Literature DB >> 17931149

The science of adjuvants.

Marcin Kwissa1, Sudhir Pai Kasturi, Bali Pulendran.   

Abstract

Adjuvants are substances that boost the immunogenicity of vaccines. However, most successful vaccines have been derived empirically and are capable of inducing robust T- and B-cell immunity without any adjuvant additives. Emerging evidence suggests that such live vaccines induce innate immune activation via a range of stimuli, including ligands specific for Toll-like receptors, which, in effect, serve as their own adjuvants. In contrast to these live vaccines, subunit vaccines need to be supplemented with adjuvants to boost their immunogenicity. However, there is a paucity of licensed adjuvants for clinical use and, thus, there is a critical need to develop safe and effective adjuvants. In this context, recent advances in innate immunity are beginning to offer new insights into how empiric vaccines and adjuvants mediate their efficacy. In this article, we review the latest progress and emerging concepts in adjuvant development, which includes novel findings in innate immune biology and their impact on vaccinology.

Mesh:

Substances:

Year:  2007        PMID: 17931149     DOI: 10.1586/14760584.6.5.673

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  39 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 2.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 3.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Authors:  Nicholas O Fischer; Ernesto Infante; Tomohiro Ishikawa; Craig D Blanchette; Nigel Bourne; Paul D Hoeprich; Peter W Mason
Journal:  Bioconjug Chem       Date:  2010-06-16       Impact factor: 4.774

5.  Evaluation of three experimental bovine viral diarrhea virus killed vaccines adjuvanted with combinations of Quil A cholesterol and dimethyldioctadecylammonium (DDA) bromide.

Authors:  Julia F Ridpath; Paul Dominowski; Ramasany Mannan; Robert Yancey; James A Jackson; Lucas Taylor; Sangita Mediratta; Robert Eversole; Charles D Mackenzie; John D Neill
Journal:  Vet Res Commun       Date:  2010-09-28       Impact factor: 2.459

Review 6.  Division of labor, plasticity, and crosstalk between dendritic cell subsets.

Authors:  Bali Pulendran; Hua Tang; Timothy L Denning
Journal:  Curr Opin Immunol       Date:  2007-12-21       Impact factor: 7.486

7.  Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy.

Authors:  Yasser A Aldhamen; Sergey S Seregin; Charles F Aylsworth; Sarah Godbehere; Andrea Amalfitano
Journal:  Int Immunol       Date:  2013-12-27       Impact factor: 4.823

8.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

9.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

10.  MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Authors:  Mark T Orr; Malcolm S Duthie; Hillarie Plessner Windish; Elyse A Lucas; Jeffrey A Guderian; Thomas E Hudson; Narek Shaverdian; Joanne O'Donnell; Anthony L Desbien; Steven G Reed; Rhea N Coler
Journal:  Eur J Immunol       Date:  2013-07-03       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.